Gore has announced that its TAG thoracic device family has exceeded 100,000 devices distributed worldwide.
The conformable TAG device is indicated in most geographical regions for aneurysms, isolated lesions including traumatic transections, and type B dissections. Designed to offer a thoracic endovascular treatment option, Gore says that the device family offers a less-invasive alternative to conventional therapy. The stent graft family has demonstrated reduced operative mortality and morbidity, providing patients with a safe and effective alternative to open repair treatments.
“Physicians desire a singular device with proven results and durability across all etiologies,” said Mark A Farber, vascular surgeon (aortic specialist), Chapel Hill, USA. “The magnitude of reaching such a large milestone exemplifies the adoption of the conformable TAG device as the standard of care in TEVAR treatment.”
Farber will speak to this achievement at the 2016 Vascular Annual Meeting (8–11 June, National Harbor, USA) during his presentation, “Durable TEVAR: Results from 100,000 Gore TAG thoracic devices distributed worldwide,” on 10 June.
A Gore press release says that the TAG device family is the most studied thoracic stent-graft available. Since the first clinical implant in 1998, the device family has been studied in 10 US Food and Drug Administration-consented clinical studies, one European clinical trial (ADSORB), and one worldwide registry (GREAT).
“Our thoracic stent-graft is the trusted solution for TEVAR procedures, with more than half of all physicians choosing the device for even the most complex cases,” said Ryan Takeuchi, aortic business unit leader at Gore. “This confidence has been built on our nearly two decades of working closely with physicians to evolve the device—pioneering thoracic endovascular aortic repair therapy and delivering conformability without compromise.”